Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
Eli Lilly and Co LLY
News
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Eli Lilly's Oral GLP-1 Associated With Reduced Risk of Type 2 Diabetes, Heart Disease in Adults With Obesity
Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials With Ely Lilly
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
Eli Lilly Gets Expanded Label Approval From FDA for Alopecia Drug
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update
United States